ClinicalTrials.gg

Program

porustobart

Also written as “HBM4003 and Triprilimab”, “Porustobart” and “HBM4003”.

Its studies are mostly in Colonic Neoplasms, led by 3 companies.

Furthest: phase 2, since Dec 8, 20205 company-led studies, 1 open or runningNext primary completion: Sep 30, 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Harbour BioMed (Guangzhou)30 open or runningphase 1since Dec 8, 2020Dec 8, 2020none ahead
Harbour BioMed US10 open or runningphase 1since Oct 15, 2019Oct 15, 2019none ahead
Solstice Oncology11 open or runningphase 2since Sep 3, 2026Sep 3, 2026Sep 30, 2029phase 2 · NCT07808151

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 15, 2019First study: phase 1 study in Advanced Solid TumorNew to Harbour BioMed USHarbour BioMed US · NCT04135261 · 65 enrolled · Australia, China, Hong Kong
  2. Dec 8, 2020Harbour BioMed (Guangzhou)'s first study: phase 1 study in Solid TumorsNew to Harbour BioMed (Guangzhou)Harbour BioMed (Guangzhou) · NCT04727164 · 61 enrolled
  3. Apr 26, 2021Phase 1 study in Solid TumorHarbour BioMed (Guangzhou) · NCT04866485 · 66 enrolled
  4. Nov 23, 2021Phase 1 study in Solid TumorsHarbour BioMed (Guangzhou) · NCT05149027 · 67 enrolled
  5. Sep 3, 2026Solstice Oncology's first study: phase 2 study in Colonic NeoplasmsNew to Solstice OncologySolstice Oncology · NCT07808151 · 100 planned · United States, Belgium, Italy and more

Ahead

  1. Sep 30, 2029Primary completion: phase 2 study in Colonic NeoplasmsSolstice Oncology · NCT07808151

TargetBeta

CTLA4 →read by rule
“A recombinant human heavy chain only antibody (HCAb) directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4;CTLA4), ”NCIt, by rule

Other programs on CTLA4

ProgramCompanyFurthest phaseStudies
tremelimumabruleAstraZenecaphase 347
cadonilimabruleAkesophase 345
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
Anti-CTLA-4 Monoclonal Antibody SHR-8068ruleJiangsu HengRui Medicinephase 316
erfonrilimabruleAlphamab Oncologyphase 314
Anti-CTLA-4 Monoclonal Antibody IBI310ruleInnovent Biologicsphase 311
gotistobartruleoncoc4-incphase 35
zalifrelimabruleAgenusphase 26
lorigerlimabruleMacroGenicsphase 24
Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rulehc-biopharma-incphase 22
GB268ruleeddingpharm-zhuhai-co-ltdphase 22

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07808151Colonic Neoplasms · United States, Belgium, Italy and more2RecruitingSolstice OncologySep 30, 2029100
NCT05149027Solid Tumors1UNKNOWNHarbour BioMed (Guangzhou)May 30, 202467
NCT04866485Solid Tumor1UNKNOWNHarbour BioMed (Guangzhou)Feb 202366
NCT04727164Solid Tumors1UNKNOWNHarbour BioMed (Guangzhou)Nov 202361
NCT04135261Advanced Solid Tumor · Australia, China, Hong Kong1CompletedHarbour BioMed USJan 17, 202365

How it is read

Names in the registry

  • “HBM4003 and Triprilimab”, 2 entries
  • “Porustobart”, 1 entry
  • “HBM4003”, 1 entry
  • “HBM4003 and pembrolizumab”, 1 entry

Codes read as this program: HBM4003.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.